Co-Diagnostics Inc (NASDAQ:CODX) (Co-Dx) has announced that it will be disclosing the global expansion of its original equipment manufacturer (OEM) agreement with Bio Molecular Systems (BMS) at the company's customer and distributor update today at the American Association for Clinical Chemistry’s (AACC) Annual Scientific Meeting & Clinical Lab Expo.
The molecular diagnostics firm said the expanded branding and distribution OEM agreement increases Co-Diagnostics' approved sales territories to 193 countries worldwide.
“We are excited for the opportunities that we believe this expanded agreement will provide the company to increase the reach of our state-of-the-art products,” Co-Diagnostics CEO Dwight Egan said in a statement.
READ: Co-Diagnostics ships monkeypox virus tests to international distributor to fight multi-country outbreak
“Co-Dx tests have already been sold to laboratories and distributors in over 50 countries, and with this expanded agreement we expect that even more areas will be able to benefit from Co-Dx's high-quality, affordable molecular testing tools,” Egan added.
Co-Diagnostics noted BMS currently manufactures the magnetic induction polymerase chain reaction (PCR) instrument that is sold by the company as the Co-Dx Box, which includes software that optimized specifically to enhance ease-of-use of the company's molecular assays.
Based in Utah, Co-Diagnostics is a molecular diagnostics company that develops, manufactures, and markets new, state-of-the-art diagnostics technologies.
Contact Sean at sean@proactiveinvestors.com